NCT01745757View on ClinicalTrials.gov

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer

CompletedOBSERVATIONAL
Enrollment

510

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions
MetastaticBreast Cancer
Interventions
DRUG

Bevacizumab

Treatments received by patients in this study are prescribed in the context of standard care

DRUG

paclitaxel

Treatments received by patients in this study are prescribed in the context of standard care

Trial Locations (19)

Unknown

Institut Bergonie, Bordeaux

Centre Francois Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Centre Georges Francois Leclerc, Dijon

CHU Grenoble, Grenoble

Centre Leon Berard, Lyon

Hôpital Européen, Marseille

Institut Paoli Calmettes, Marseille

Centre Val d'Aurelle, Montpellier

Centre Catherine de Sienne, Nantes

Centre Antoine Lacassagne, Nice

Institut Curie, Paris

Institut Jean Godinot, Reims

Centre Hospitalier, Roanne

Institut Curie, Saint-Cloud

Centre Paul Strauss, Strasbourg

Institut Claudius Regaud, Toulouse

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER

NCT01745757 - Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter